Powder: -20°C for 3 years | In solvent: -80°C for 2 years
CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50: 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM. This compound also inhibits PC-3 cell migration (IC50: 4.2 μM), as determined by a scratch wound assay. CCG-203971 causes no cytotoxicity when evaluated by the WST-1 assay. It is well tolerated in normal mice up to doses of 100 mg/kg given intraperitoneally over five days.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 31.00 | |
10 mg | In stock | $ 52.00 | |
25 mg | In stock | $ 97.00 | |
50 mg | In stock | $ 169.00 | |
100 mg | In stock | $ 263.00 | |
500 mg | In stock | $ 643.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 34.00 |
Description | CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50: 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM. This compound also inhibits PC-3 cell migration (IC50: 4.2 μM), as determined by a scratch wound assay. CCG-203971 causes no cytotoxicity when evaluated by the WST-1 assay. It is well tolerated in normal mice up to doses of 100 mg/kg given intraperitoneally over five days. |
Targets&IC50 | SRE.L:0.64 μM |
Synonyms | CCG203971 |
Molecular Weight | 408.88 |
Formula | C23H21ClN2O3 |
CAS No. | 1443437-74-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
DMSO: 73 mg/mL(178.5 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CCG-203971 1443437-74-8 Cell Cycle/Checkpoint GPCR/G Protein MAPK Rho Ras Inhibitor SRF CCG 203971 MKL1 CCG203971 inhibit MRTF anti-metastasis PC-3 migration inhibitor